SCHEMBL6415002

SCHEMBL6415002

Cc1ccc(Nc2nc3nonc3nc2N/N=C\c2ccc(-c3cc(C)cc([N+](=O)[O-])c3C)o2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BIRC5 O15392 1/20 0.46
MAPT P10636 7/20 0.41
KMT2A Q03164 7/20 0.41
MEN1 O00255 6/20 0.41
NPSR1 Q6W5P4 1/20 0.41
ALDH1A1 P00352 7/20 0.41
NSD2 O96028 1/20 0.41
KDM4C Q9H3R0 1/20 0.41
TDP1 Q9NUW8 2/20 0.40
RAB9A P51151 2/20 0.40
POLB P06746 1/20 0.40
MCL1 Q07820 1/20 0.40
GAA P10253 4/20 0.39
RECQL P46063 2/20 0.39
IDO1 P14902 1/20 0.39
THRB P10828 1/20 0.38
LMNA P02545 2/20 0.38
KDM4E B2RXH2 1/20 0.38
HPGD P15428 2/20 0.37
CYP1A2 P05177 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6415008 1.00 BIRC5 (0.46) BIRC5MAPTKMT2AMEN1NPSR1
SCHEMBL13310261 0.86 BIRC5 (0.50) BIRC5MAPTKMT2AMEN1NPSR1
SCHEMBL3051656 0.76 BIRC5 (0.49) BIRC5MAPTKMT2AMEN1NPSR1
SCHEMBL3051653 0.76 BIRC5 (0.49) BIRC5MAPTKMT2AMEN1NPSR1
SCHEMBL6434942 0.76 ALDH1A1 (0.44) MAPTKMT2AMEN1NPSR1ALDH1A1
SCHEMBL6434947 0.76 ALDH1A1 (0.44) MAPTKMT2AMEN1NPSR1ALDH1A1
SCHEMBL6506319 0.75 MET (0.52) BIRC5MAPTKMT2AMEN1NPSR1
SCHEMBL6503291 0.75 MET (0.52) BIRC5MAPTKMT2AMEN1NPSR1
SCHEMBL3058288 0.75 MEN1 (0.54) BIRC5MAPTKMT2AMEN1NPSR1
SCHEMBL3058290 0.75 MEN1 (0.54) BIRC5MAPTKMT2AMEN1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 BIRC5 2525/4885MAPT 4420/4885KMT2A 3640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.